These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10408367)

  • 1. Therapeutic intervention with complement and beta-glucan in cancer.
    Ross GD; Vetvicka V; Yan J; Xia Y; Vetvicková J
    Immunopharmacology; 1999 May; 42(1-3):61-74. PubMed ID: 10408367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
    Vetvicka V; Thornton BP; Ross GD
    J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
    Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
    J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
    Vetvicka V; Thornton BP; Wieman TJ; Ross GD
    J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
    Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
    J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.
    Yan J; Vetvicka V; Xia Y; Hanikýrová M; Mayadas TN; Ross GD
    Immunopharmacology; 2000 Jan; 46(1):39-54. PubMed ID: 10665778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
    Ramos OF; Patarroyo M; Yefenof E; Klein E
    J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
    Li B; Allendorf DJ; Hansen R; Marroquin J; Ding C; Cramer DE; Yan J
    J Immunol; 2006 Aug; 177(3):1661-9. PubMed ID: 16849475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein.
    Ross GD
    Crit Rev Immunol; 2000; 20(3):197-222. PubMed ID: 10968371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.
    Ross GD; Vĕtvicka V
    Clin Exp Immunol; 1993 May; 92(2):181-4. PubMed ID: 8485905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of membrane complement receptor type three (CR3) for beta-glucans.
    Ross GD; Cain JA; Myones BL; Newman SL; Lachmann PJ
    Complement; 1987; 4(2):61-74. PubMed ID: 3040332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.
    Klein E; Di Renzo L; Yefenof E
    Mol Immunol; 1990 Dec; 27(12):1343-7. PubMed ID: 1980339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of beta-glucans on the immune system.
    Akramiene D; Kondrotas A; Didziapetriene J; Kevelaitis E
    Medicina (Kaunas); 2007; 43(8):597-606. PubMed ID: 17895634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments.
    Ramos OF; Nilsson B; Nilsson K; Eggertsen G; Yefenof E; Klein E
    Cell Immunol; 1989 Apr; 119(2):459-69. PubMed ID: 2522826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18).
    Roubey RA; Ross GD; Merrill JT; Walton F; Reed W; Winchester RJ; Buyon JP
    J Immunol; 1991 May; 146(10):3557-62. PubMed ID: 1673986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.
    Bose N; Chan AS; Guerrero F; Maristany CM; Qiu X; Walsh RM; Ertelt KE; Jonas AB; Gorden KB; Dudney CM; Wurst LR; Danielson ME; Elmasry N; Magee AS; Patchen ML; Vasilakos JP
    Front Immunol; 2013; 4():230. PubMed ID: 23964276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
    Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
    J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
    Thornton BP; Vĕtvicka V; Pitman M; Goldman RC; Ross GD
    J Immunol; 1996 Feb; 156(3):1235-46. PubMed ID: 8558003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.